Skip to main content
Explore URMC
menu

Jane Larae Liesveld, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-4099

Office: (585) 275-5823

Fax: (585) 273-1051

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

While the doctor-patient relationship is one of potential intensity and privacy, the best patient care comes from teamwork, which values all who contribute to achieving high-quality care with compassion. Providing patients and their families with the knowledge and means to be partners in care is one of my key roles as a physician.

When a patient is diagnosed with a blood cancer or chronic blood condition, it is often the start of a new journey that will be the beginning of great change. Walking with patients through this journey from start to finish, and offering therapy and guidance along the way, is a source of professional and personal satisfaction for me. Hematology/oncology is a field where clinical and basic research can be rapidly applied to improve outcomes and quality of life.

I grew up in the Midwest, but have lived in Rochester since I began my post-doctoral medical training. My association with Strong, the University of Rochester and the people in our community and surrounding areas has enriched my life. I feel privileged to work in such a wonderful environment. I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation.

Conditions I Treat

- Leukemia, all types
- Myeloproliferative disorders
- Myelodysplastic syndromes
- Multiple myeloma
- Stem cell transplantation

Research

Effects of oxygen metabolites/chemokines on hematopoietic stem cell expansion and preservation.

Effects of hematopoietic growth factors and inhibitors on AML blast proliferation (correlative clinical studies)

Effects of hematopoietic stem cell adhesion on marrow stromal cell cytokine production.

Role of signal transduction inhibition in treatment of acute myelogenous leukemia/myelodysplasia.

Characterization of mobilized peripheral blood stem cells

Credentials

Education

1980
MD | University of Iowa College of Medicine

Post-doctoral Training & Residency

07/01/1988 - 06/30/1989
Research in Hematology Research Fellowship at University of Rochester Medical Center

07/01/1987 - 06/30/1988
Fellowship in Oncology at University of Rochester Medical Center

07/01/1984 - 06/30/1987
Fellowship in Hematology at University of Rochester Medical Center

07/01/1981 - 06/30/1984
Residency in Medicine at University of Rochester Medical Center

07/01/1980 - 06/30/1981
Internship in Medicine at University of Rochester Medical Center

VIEW ALL expand_more

Awards

2009
Gilda's Club of Rochester Jacob Gitelman Award

2007
Hematology-Oncology Fellowship Teaching Award

2005 - 2007
Aplastic Anemia and MDS International Foundation Gordon Forgash Research Award

2004 - 2006
Lawrence A. Kohn Senior Teaching Fellowship
Sponsor: University of Rochester Department of Medicine

1998 - 2003
Leukemia Society of America, Clinical Scholar Award

1989 - 1992
Leukemia Society of America Special Fellowship

1989 - 1992
James P. Wilmot Postdoctoral Cancer Research Fellowship

1987 - 1988
American Cancer Society Clinical Fellowship Award

VIEW ALL expand_more

Clinical Trials

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications (NMDP 10-CBA)

Lead Researcher: Jane Larae Liesveld MD

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

View Study Details

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Lead Researcher: Jane Larae Liesveld MD

This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

View Study Details

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Lead Researcher: Jane Larae Liesveld MD

This phase II/III trial studies how well daunorubicin and cytarabine with or without uproleselan works in treating older adult patients with acute myeloid leukemia receiving intensive induction chemotherapy. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Uproleselan may prevent cancer from returning or getting worse. Giving daunorubicin and cytarabine with uproleselan may work better in treating patients with acute myeloid leukemia compared to daunorubicin and cytarabine alone.

View Study Details

Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia

Lead Researcher: Jane Larae Liesveld MD

A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase.

View Study Details

Patents

Patent Title: Continuous Flow Chamber Device for Separation, Concentration and/or Purification of Cells
Patent #: 7,892,766
Issue Date: Feb 22, 2011
Country: United States
Invented By: Nichola Charles, Nathan Clark, John P Gentile, Michael R King, Jane Liesveld, Nipa Anand Mody

Publications

Journal Articles

9/21/2021
Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao NJ, Rizzieri D, Gale RP, Gadalla SM, Cairo MS, Mussetti A, Gore SD, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson CN, Diaz Perez MA, Cassaday R, Savani BN, Ballen KK, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel M, van der Poel MWM, Grunwald MR, Liesveld JL, Kamble RT, McGuirk JP, Munker R, Cahn JY, Lee JW, Freytes CO, Krem M, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe HK, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow MR, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W. "Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia." Blood advances.. 2021 Sep 21; Epub 2021 Sep 21.

9/20/2021
DeAngelo DJ, Jonas BA, Liesveld JL, Bixby DL, Advani AS, Marlton P, Magnani JL, Thackray HM, Feldman EJ, O'Dwyer ME, Becker PS. "Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia." Blood.. 2021 Sep 20; Epub 2021 Sep 20.

9/15/2021
Locastro M, Baran A, Liesveld JL, Huselton EJ, Becker MW, O'Dwyer KM, Aljitawi OS, Baumgart M, Snyder E, Kluger B, Loh KP, Mendler JH. "Portable Medical Orders and End of Life Measures in Acute Myeloid Leukemia and Myelodysplastic Syndromes." Blood advances.. 2021 Sep 15; Epub 2021 Sep 15.

Books & Chapters

2017
Chapter Title: Stem Cell Mobilization
Book Title: In: Encyclopedia of Cancer
Author List: Liesveld, JL
Edited By: Schwab, M
Published By: Springer-Verlag 2017

2016
Chapter Title: Chronic Myelogenous Leukemia and Related Disorders
Book Title: In: Williams Hematology
Author List: Liesveld, JL and Lichtman, MA
Edited By: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, Caligiuri MA,
Published By: McGraw Hill 2016 in New York, NY

2016
Chapter Title: Acute Myelogenous Leukemia
Book Title: In: Williams Hematology
Author List: Liesveld, JL and Lichtman, MA
Edited By: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, Caligiuri MA
Published By: McGraw Hill 2016 in New York, NY

VIEW ALL PUBLICATIONS

Videos

play_circle_filled

SECOND OPINION | Leukemia (CLL) | APT

play_circle_filled

SECOND OPINION | Leukemia (CLL) | APT | Full Episode